aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-05-19 12:00Core Insights - The ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis has a balanced demographic and disease characteristic profile, representative of the target trial population [1][4] - Real-world evidence indicates that the target market for efzofitimod is larger than previously estimated, with increased morbidity among patients [1][3] - Approximately 75% of diagnosed pulmonary sarcoidosis patients in the U.S. require treatment with steroids, highlighting the reliance on corticosteroids despite their limited clinical evidence and side effects [1][3][6] Company Overview - aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][10] - The lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), specifically targeting pulmonary sarcoidosis and systemic sclerosis-related ILD [9][10] Clinical Study Details - The Phase 3 EFZO-FIT™ study has enrolled 268 patients, with 264 dosed and included in the analysis, focusing on a moderate to severe chronic symptomatic pulmonary sarcoidosis population [7][8] - The mean baseline oral corticosteroid dose among participants was 10.55 mg, with 38.3% on steroid-sparing immunosuppressants at baseline [7] Treatment Landscape - Glucocorticoids remain the most common treatment for pulmonary sarcoidosis, with higher usage rates than previously reported [6] - Treatment intensity escalates over time, with patients rapidly progressing to later-line therapies, and 10% of non-incident patients requiring high-cost, off-label biologics within three years [6] Epidemiological Insights - Approximately 158,900 individuals in the U.S. have pulmonary sarcoidosis with parenchymal involvement, with an estimated 30,000 new cases diagnosed annually [12] - The disease disproportionately affects women and Black individuals, with 1 in 8 patients hospitalized within three years, and an average hospital stay exceeding 5 days [12]